Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 8, Pages 1758
Publisher
MDPI AG
Online
2021-04-07
DOI
10.3390/cancers13081758
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study
- (2021) Daniel C. Beachler et al. BMC CANCER
- Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases
- (2021) Charles Khouri et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Long‐Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Updated Analysis With Up to 5 Years of Follow‐Up
- (2021) Richard S. Finn et al. ONCOLOGIST
- CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
- (2021) Michela Roberto et al. Cancers
- CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice
- (2021) Malinda T. West et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
- (2021) Hope S. Rugo et al. ONCOLOGIST
- Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
- (2020) Santa Cirmi et al. Cancers
- Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials
- (2020) Kyaw Zin Thein et al. BREAST CANCER RESEARCH AND TREATMENT
- Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
- (2020) Milo Gatti et al. DRUG SAFETY
- Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
- (2020) Emanuel Raschi et al. Targeted Oncology
- Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
- (2020) Stefanie L. Groenland et al. CLINICAL PHARMACOKINETICS
- CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
- (2020) Rossana Roncato et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
- (2020) C. Louwrens Braal et al. DRUGS
- CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis
- (2020) Concetta E. Onesti et al. Expert Review of Anticancer Therapy
- Update on Guidelines for the Management of Cancer‐Associated Thrombosis
- (2020) Michael B. Streiff et al. ONCOLOGIST
- Coronary Plaque Erosion After Abemaciclib Treatment Onset: An Unknown Side Effect?
- (2020) Alberto Vera et al. THROMBOSIS AND HAEMOSTASIS
- Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
- (2019) Fausto Petrelli et al. BREAST CANCER RESEARCH AND TREATMENT
- Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
- (2019) Emanuel Raschi et al. Targeted Oncology
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors
- (2019) Lorenzo Gervaso et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
- (2018) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- A Real-World Experience of Palbociclib-Induced Adverse Events and Compliance with Complete Blood Count (CBC) Monitoring in Women with Hormone Receptor (HR) -Positive/Her2-Negative Metastatic Breast Cancer
- (2018) G.A. Watson et al. Clinical Breast Cancer
- Cyclin-Dependent Kinase Inhibitor–Associated Thromboembolism
- (2018) Sven R. Olson et al. JAMA Oncology
- Good Signal Detection Practices: Evidence from IMI PROTECT
- (2016) Antoni F. Z. Wisniewski et al. DRUG SAFETY
- A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases
- (2015) Mickael Arnaud et al. DRUG SAFETY
- Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
- (2013) R Harpaz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Quantitative signal detection using spontaneous ADR reporting
- (2009) A. Bate et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search